• Loading metrics

Zoonotic Epidemic of Sporotrichosis: Cat to Human Transmission

  • Isabella Dib Ferreira Gremião ,

    Affiliation Laboratory of Clinical Research on Dermatozoonosis in Domestic Animals, Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil

  • Luisa Helena Monteiro Miranda,

    Affiliation Laboratory of Clinical Research on Dermatozoonosis in Domestic Animals, Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil

  • Erica Guerino Reis,

    Affiliation Laboratory of Clinical Research on Dermatozoonosis in Domestic Animals, Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil

  • Anderson Messias Rodrigues,

    Affiliation Cell Biology Division, Department of Microbiology, Immunology and Parasitology, Federal University of São Paulo (UNIFESP), São Paulo, São Paulo, Brazil

  • Sandro Antonio Pereira

    Affiliation Laboratory of Clinical Research on Dermatozoonosis in Domestic Animals, Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil

Zoonotic Epidemic of Sporotrichosis: Cat to Human Transmission

  • Isabella Dib Ferreira Gremião, 
  • Luisa Helena Monteiro Miranda, 
  • Erica Guerino Reis, 
  • Anderson Messias Rodrigues, 
  • Sandro Antonio Pereira


Most of the 51 species embedded in the genus Sporothrix are nonpathogenic environmental fungi that are closely related to decaying wood, plants, and soil. However, members of the Sporothrix schenckii complex are highly successful mammal pathogens, including S. brasiliensis, S. schenckii sensu stricto (s. str.), S. globosa, and S. luriei, the causative agents of human and animal sporotrichosis [1]. Their key to success during mammal infection lies at least in part with their ability to change from a mycelial saprophytic lifestyle at 25°C in the environment to a parasitic yeast cell at an elevated temperature (35°C–37°C), such as those developed by warm-blooded hosts [2].

Typically, infection develops after traumatic inoculation of contaminated soil, plants, and organic matter into skin or mucosa. Alternatively, infection may occur during the animal transmission (cat–cat or cat–dog) and zoonotic transmission (cat–human), which has been mostly associated with scratches or bites from infected cats [2]. In Brazil, S. brasiliensis is repeatedly associated with feline infection and has consistently shown higher virulence during epizootics, as well as in murine models of sporotrichosis. A hallmark of S. brasiliensis infection is its tendency to escalate to outbreaks or epidemics among cats with high potential for zoonotic transmission.

Sporotrichosis is an emergent disease and, over the past two decades, the incidence of zoonotic sporotrichosis has been on the rise, particularly in Brazil. Judging from the epizootic and zoonotic epidemics taking place in Rio de Janeiro, Brazil, tackling sporotrichosis requires the engagement of animal and human health policies to reduce the transmission chain of Sporothrix.

Infected Cat: Key Point in Zoonotic Transmission

Cat-transmitted sporotrichosis has been documented in isolated cases or in small outbreaks in the American and Asian continents. Interestingly, although isolated cases of feline sporotrichosis have been documented in Australia, Spain, Japan, and Germany, there are no reports of zoonotic transmission from these regions [36] (Fig 1A).

Fig 1. Feline sporotrichosis cases around the world, 1952–2016.

(A) Since the mid-20th century, feline sporotrichosis has typically occurred in isolated cases and small outbreaks, and only a few reports of zoonotic transmission have been described in the literature. The Southeast Brazil region has the largest absolute number of cases with an overwhelming prevalence of S. brasiliensis during epizootic outbreaks. Outside Brazil, most feline cases are due to the classical agent S. schenckii. (B) Spatiotemporal evolution of feline sporotrichosis cases in Brazil. Over the last two decades (1998–2016), Brazil has experienced a long-lasting outbreak of cat-transmitted sporotrichosis in Rio de Janeiro, with 4,669 cases reported. Cat-borne sporotrichosis due to S. brasiliensis often appears in the form of outbreaks or epidemics within a short period of time. Remarkably, before the 1990s, Rio de Janeiro reported a low number of cases, nearly always unrelated to feline transmission types.

In the United States, isolated cases or small outbreaks were reported from 1952 to 2011, and S. schenckii was the etiologic agent [79]. In Mexico, where the predominant etiologic agent is S. schenckii s. str. [10], only one case of zoonotic sporotrichosis was described related to a scratch of an infected cat in 2008 [11].

Between 2011 and 2014, four cases of human sporotrichosis related to cats were reported in Buenos Aires, Argentina. To our knowledge, this is the first report of zoonotic sporotrichosis in this country [12]. Even though the causative species has not yet been reported, the proximity to the Southern region of Brazil and the type of transmission suggests that S. brasiliensis may be the species involved in these cases.

In Malaysia, 12 cases of zoonotic transmission related to cats were reported between 1990 and 2010, and five of them were from a small outbreak [1314]. Recently, 18 clinical isolates from cats in Malaysia were identified as S. schenckii s. str., the prevailing causative agent of the feline sporotrichosis in this country [10]. In India, one case of zoonotic transmission was reported in 2009, and samples from the patient and his cat were positive for S. schenckii s. str. [15].

Although cats are a source of infection and a key to transmission, the evaluation of the feline population in endemic areas were performed in Brazil and Peru [1617]. Curiously, in an endemic region in Peru, where zoonotic transmission was not recorded, Sporothrix was isolated from the nasal cavity and/or nails of two cats (2.38%) without clinical signs of sporotrichosis [17].

An Unprecedent Zoonotic Epidemic

From 1997 to 2011, 4,188 human cases were recorded at Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, the main referral center for the treatment of this mycosis in Brazil [18]. Since 1998, 244 dogs were diagnosed through 2014 [19], and 4,703 cats were diagnosed through 2015. Due to the high incidence of feline sporotrichosis, Rio de Janeiro is presently considered hyperendemic for cat-associated sporotrichosis [2]. However, these cases were recorded from only one institution, so they do not truly reflect the actual picture of this disease in this region. Cases of feline sporotrichosis and zoonotic transmission have been reported in other Brazilian states, especially in Rio Grande do Sul and São Paulo; however, the reported number in these regions is much smaller compared to Rio de Janeiro [2] (Fig 1B). Despite the fact that this is the largest number of canine sporotrichosis cases ever documented, there were no reports of zoonotic transmission from dogs in the Rio de Janeiro epidemic. Dogs are not directly involved in the transmission of the Sporothrix spp., probably due to the scarcity of fungal organisms in their lesions in the majority of the cases [20].

Overcoming Drug Resistance: A Treatment Challenge

Treatment usually requires long-term administration of itraconazole, potassium iodide, or amphotericin B, depending on the severity and location of the lesions. Genotyping of Sporothrix during cat-transmitted sporotrichosis associated with antifungal susceptibility profiles raised concern for the emergence and spread of drug-insensitive strains [2122]. Remarkably, studies reported an increasing number of amphotericin B and itraconazole-insensitive strains over time [21]. Identifying these epidemiological trends associated with the emergence of drug resistance is important to adjust antifungal therapy and to encourage the development of new drugs to treat sporotrichosis. Currently, potential alternative therapies to impair Sporothrix development and tackle sporotrichosis include terpinen-4-ol and farnesol [23], miltefosine [24], TCAN26 (a structural analogue of miltefosine) [25], and H3 (a 24-sterol methyltransferase inhibitor) [26].

Successful treatment outcomes will also rely on rapid and accurate diagnosis, especially when dissimilar antifungal susceptibility profiles are noted among different Sporothrix species. A cost-effective option includes the molecular diagnosis based on species-specific PCR using primers targeting the calmodulin-encoding gene from pathogenic Sporothrix. This PCR-based method is able to detect Sporothrix DNA with high sensitivity and specificity from infected specimens even in the presence of DNA from the warm-blooded host [27].

A Highly Virulent Pathogen Meets a Susceptible Host

Cell-mediated immunity is thought to play an important role in the control of feline sporotrichosis, since increased percentages of CD4 cells are correlated with single lesions, well-organized inflammation, and lower fungal burden. However, most cats with sporotrichosis display lesions with poorly-formed granulomas and high fungal burden, which generally correlated with CD8low cell subsets [28]. Interestingly, this subset is referred to as greatly enhanced by a Th2-shifted environment [29], while the host protective immunity to fungal infections seems to rely largely on a Th1-biased response [30]. Still, the underlying mechanisms leading to different presentations of feline sporotrichosis are undetermined.

Severe feline sporotrichosis may develop independently of retrovirus coinfections, which are known to cause immunosuppression in cats. In most of the endemic areas of Rio de Janeiro, the cats are usually allowed to roam outdoors, and most of them are not vaccinated nor neutered and do not receive regular prophylactic deworming. Therefore, the population of stray cats is large, and the contribution of other infectious diseases to the susceptibility of cats to sporotrichosis cannot be ruled out. In fact, fungal and parasitic infections elicit conflicting immune pathways that may counterbalance each other. In contrast to the antifungal immunity, the classical defense mechanisms to helminth infections include increase of IL-10 and Th2 cytokines, with the suppression of Th1 cytokines [31]. Therefore, we expect this kind of parasite–Sporothrix coinfection to increase susceptibility to sporotrichosis. Accordingly, changes in cytokine profile and the lack of fungal clearance are reported in rats with experimental sporotrichosis coinfected by Taenia taeniaeformis [32]. We have no clear information about which cytokines drive mechanisms of immune response in cats with sporotrichosis and whether helminth coinfection shifts the inflammatory environment. Even so, we hypothesize that helminth infection control in cats with sporotrichosis could balance the immune response in favor of a Th1 type and contribute to the fungal clearance with a reduction on their zoonotic potential.

It is also possible that an increased virulence of S. brasiliensis may be a factor contributing to the sporotrichosis outbreak in Rio de Janeiro. Experimental model systems from mice to invertebrates have been used to investigate the emergence of pathogenicity of Sporothrix and bring attention to differences in pathology and virulence factors, where S. brasiliensis usually display higher fungal burden, invasiveness, and extensive tissue damage when compared to the remaining agents in the S. schenckii complex [33]. In support of this hypothesis, an increasing virulence of S. brasiliensis over the years of infection was reported in a patient and assigned to improve fungal resistance to host’s oxidative stress [34].

Recently, the distinct sensititivities to oxidative stress between S. brasiliensis and S. schenckii were correlated with the Hog-1 stress-induced kinase pathway [35]. The production of melanin is also associated with resistance to phagocytosis in more pathogenic isolates of Sporothrix, notably to S. brasiliensis [36]. Cell wall lipids are also able to inhibit the phagocytosis [37], and yeasts of Sporothrix are more virulent than longer-term culture conidia, which is thought to reflect enhanced evasion of phagocytosis [38]. Unlike classic transmission of Sporothrix, due to inoculation of asexual spores, zoonotic transmission is thought to be mediated by yeast cells. Innate immunity plays a role in the development of adaptive response, by recognizing fungal wall elements through Toll-like receptors [37]. Thus, the direct inoculation of yeast could lead to more challenging host–pathogen interactions and be crucial for the establishment of the infection. We speculate that the evasion of the yeast cells could take part in the typical development of lesions [28] with macrophages apparently unable to complete phagocytosis in feline sporotrichosis and prevent further activation of adaptive immunity. Fungal wall compounds are also important in the adhesion to extracellular matrix, in particular 3-carboxymuconate cyclase (glycoprotein Gp70 and Gp60) [3940]. The glycoprotein Gp60 has also been suggested to act as a virulence factor, as it is associated with more virulent isolates of Sporothrix, principally S. brasiliensis [40].

Vaccine Candidates and Perspectives

A specific and protective humoral response against Sporothrix has already been observed [4041] and may be a clue for the further investigation of vaccine candidates. Sporothrix 3-carboxymuconate cyclase has emerged as a potential target for vaccination studies [40,42]. Since both Gp70 and Gp60 are recognized by antibodies in serum from cats with sporotrichosis [40], and considering that these cats are a potent and major source of Sporothrix in Brazilian epidemics, an effective vaccine to prevent their infection or control their fungal burden would be a principal measure to reduce transmission.

Studies to identify a vaccine candidate and the ideal adjuvant are ongoing [40,43]. Promising results using S. schenckii cell wall protein in an aluminum hydroxide (AH) adjuvanted formulation have been reported [43]. However, the use of AH as an adjuvant should be carefully reviewed for future studies in cats, since this compound is involved in feline vaccine-induced sarcomas [44]. Passive immunization or the nonadjuvanted formulation should therefore be studied initially. Even though, the recent progress in the search for vaccine antigens and adjuvants herein discussed is encouraging especially as an important aid for controlling the enormous health burden of feline sporotrichosis in endemic areas [42]. Therefore, we raise the cats as the key host for further vaccine investigations.


The authors are grateful to James Czarnecki for the careful English review of the article.


  1. 1. Rodrigues AM, de Melo Teixeira M, de Hoog GS, Schubach TM, Pereira SA, Fernandes GF, et al. Phylogenetic analysis reveals a high prevalence of Sporothrix brasiliensis in feline sporotrichosis outbreaks. PLoS Negl Trop Dis. 2013 Jun;7(6):e2281. pmid:23818999
  2. 2. Rodrigues AM, de Hoog GS, de Camargo ZP. Sporothrix species causing outbreaks in animals and humans driven by animal-animal transmission. PLoS Pathog. 2016 Jul;12(7):e1005638. pmid:27415796
  3. 3. Mackay BM, Menrath VH, Ridley MF, Kellym WR. Sporotrichosis in a cat. Aust Vet Practit. 1986 Mar; 16(1):3–5.
  4. 4. Gonzalez Cabo JF, de las Heras Guillamon M, Latre Cequiel MV, Garcia de Jalon Ciercoles JA. Feline sporotrichosis: a case report. Mycopathologia. 1989 Dec;108(3):149–154. pmid:2615803
  5. 5. Hirano M, Watanabe K, Murakami M, Kano R, Yanai T, Yamazoe K, et al. A case of feline sporotrichosis. J Vet Med Sci. 2006 Apr;68(3):283–284. pmid:16598175
  6. 6. Scheufen S, Strommer S, Weisenborn J, Prenger-Berninghoff E, Thom N, Bauer N, et al. Clinical manifestation of an amelanotic Sporothrix schenckii complex isolate in a cat in Germany. JMM Case Rep. 2015 Aug; 2(4).
  7. 7. Singer JI, Muncie JE. Sporotrichosis; etiologic considerations and report of additional cases from New York. N Y State J Med. 1952 Sep 1;52(17:1):2147–2153.
  8. 8. Reed KD, Moore FM, Geiger GE, Stemper ME. Zoonotic transmission of sporotrichosis: case report and review. Clin Infect Dis. 1993 Mar;16(3):384–387. pmid:8095815
  9. 9. Rees RK, Swartzberg JE. Feline-transmitted sporotrichosis: A case study from California. Dermatol Online J. 2011 Jun;17(6):2. Available from: pmid:21696682
  10. 10. Zhang Y, Hagen F, Stielow B, Rodrigues AM, Samerpitak K, Zhou X, et al. Phylogeography and evolutionary patterns in Sporothrix spanning more than 14000 human and animal case reports. Persoonia. 2015 Dec; 35:1–20. pmid:26823625
  11. 11. Bove-Sevilla PM, Mayorga-Rodríguez J, Hernández-Hernández O. [Sporotrichosis transmitted by a domestic cat. Case report]. Med Cutan Iber Lat Am. 2008 Jan-Feb;36(1):33–35. Spanish.
  12. 12. Fernández N, Iachini R, Farias L, Pozzi N, Tiraboschi I. Esporotricosis, una zoonosis em alerta. In: Proceedings of the Infocus 2015; 2015 Nov 5–7; Córdoba, Argentina.Círculo Médico de Córdoba; 2015. p. 11. Spanish. Available from:
  13. 13. Zamri-Saad M, Salmiyah TS, Jasni S, Cheng BY, Basri K. Feline sporotrichosis: an increasingly important zoonotic disease in Malaysia. Vet Rec. 1990 Nov 10;127(19):480. pmid:2270639
  14. 14. Tang MM, Tang JJ, Gill P, Chang CC, Baba R. Cutaneous sporotrichosis: a six-year review of 19 cases in a tertiary referral center in Malaysia. Int J Dermatol. 2012 Jun;51(6):702–708. pmid:22607289
  15. 15. Yegneswaran PP, Sripathi H, Bairy I, Lonikar V, Rao R, Prabhu S. Zoonotic sporotrichosis of lymphocutaneous type in a man acquired from a domesticated feline source: report of a first case in southern Karnataka, India. Int J Dermatol. 2009 Nov;48(11):1198–1200. pmid:20064175
  16. 16. Schubach TM, Schubach A, Okamoto T, Barros MB, Figueiredo FB, Cuzzi T, et al. Evaluation of an epidemic of sporotrichosis in cats: 347 cases (1998–2001). J Am Vet Med Assoc. 2004 May;224(10):1623–1629. pmid:15154732
  17. 17. Kovarik CL, Neyra E, Bustamante B. Evaluation of cats as the source of endemic sporotrichosis in Peru. Med Mycol. 2008 Feb;46(1):53–56. pmid:17885948
  18. 18. Silva MB, Costa MM, Torres CC, Galhardo MC, Valle AC, Magalhães M de A, et al. [Urban sporotrichosis: a neglected epidemic in Rio de Janeiro, Brazil]. Cad Saude Publica. 2012 Oct;28(10):1867–1880. Portuguese. pmid:23090167
  19. 19. Viana PG, Pereira AS, Mutis MCS, Figueiredo FB, Miranda LHM, Antonio IMC, et al. Clinical and epidemiological aspects of the largest epidemic of sporotrichosis in dogs: 203 cases [2004–2014]. In: Proceeding of the 7th Trends in Medical Mycology; 2015 Oct; Lisbon, Portugal. Mycoses. 2015;58 (Suppl. 4), p.145.
  20. 20. Schubach TM, Schubach A, Okamoto T, Barros MB, Figueiredo FB, Cuzzi T, et al. Canine sporotrichosis in Rio de Janeiro, Brazil: clinical presentation, laboratory diagnosis and therapeutic response in 44 cases (1998–2003). Med Mycol. 2006 Feb;44(1):87–92. pmid:16805098
  21. 21. Rodrigues AM, de Hoog GS, de Cassia Pires D, Brihante RSN, Sidrim JJ da C, Gadelha MF, et al. Genetic diversity and antifungal susceptibility profiles in causative agents of sporotrichosis. BMC Infect Dis. 2014 Apr;14:219. pmid:24755107
  22. 22. Borba-Santos LP, Rodrigues AM, Gagini TB, Fernandes GF, Castro R, de Camargo ZP, et al. Susceptibility of Sporothrix brasiliensis isolates to amphotericin B, azoles, and terbinafine. Med Mycol. 2015 Feb; 53(2):178–188. pmid:25394542
  23. 23. Brilhante RS, Silva NF, Marques FJ, Castelo-Branco Dde S, de Lima RA, Malaquias AD, et al. In vitro inhibitory activity of terpenic derivatives against clinical and environmental strains of the Sporothrix schenkii complex. Med Mycol. 2015 Feb;53(2):93–98. pmid:25541558
  24. 24. Borba-Santos LP, Gagini T, Ishida K, de Souza W, Rozental S. Miltefosine is active against Sporothrix brasiliensis isolates with in vitro low susceptibility to amphotericin B or itraconazole. J Med Microbiol. 2015 Apr;64(Pt 4):415–422. pmid:25681323
  25. 25. Borba-Santos LP, Ishida K, Calogeropoulou T, de Souza W, Rozental S. Adamantylidene-substituted alkylphosphocholine TCAN26 is more active against Sporothrix schenckii than miltefosine. Mem Inst Oswaldo Cruz. 2016 Aug;111(8): 523–527. pmid:27581121
  26. 26. Borba-Santos LP, Visbal G, Gagini T, Rodrigues AM, De Camargo ZP, Lopes-Bezerra LM, et al. Δ(24)-Sterol Methyltransferase Plays an Important Role in the Growth and Development of Sporothrix schenckii and Sporothrix brasiliensis. Front Microbiol. 2016 Mar;7:311. pmid:27014234
  27. 27. Rodrigues AM, de Hoog GS, de Camargo ZP. Molecular diagnosis of Pathogenic Sporothrix species. PLoS Negl Trop Dis. 2015 Dec;9(12):e0004190. pmid:26623643
  28. 28. Miranda LH, Santiago M de A, Schubach TM, Morgado FN, Pereira SA, Oliveira R de V, et al. Severe feline sporotrichosis associated with an increased population of CD8low cells and a decrease in CD4+ cells. Med Mycol. 2016 Jan; 54(1):29–39. pmid:26483429
  29. 29. Kienzle N, Olver S, Buttigieg K, Groves P, Janas ML, Baz A, et al. Progressive differentiation and commitment of CD8+ T cells to a poorly cytolytic CD8low phenotype in the presence of IL-4. J Immunol. 2005 Feb; 174(4): 2021–2029. pmid:15699131
  30. 30. Van de Veerdonk FL, Netea MG. T-cell subsets and antifungal host defenses. Curr Fungal Infect Rep. 2010 Dec; 4(4):238–243. pmid:20976286
  31. 31. Elliott DE, Weinstock JV. Helminth-host immunological interactions: prevention and control of immune-mediated diseases. Ann N Y Acad Sci. 2012 Jan; 1247:83–96. pmid:22239614
  32. 32. Zhang X, Zhang J, Huang H, Xue R, Hu X, Li M, et al. Taenia taeniaeformis in rat favors protracted skin lesions caused by Sporothrix schenckii infection: Dectin-1 and IL-17 are dispensable for clearance of this fungus. PLoS One. 2012 Dec; 7(12):e52514. pmid:23285072
  33. 33. Fernandes GF, dos Santos PO, Rodrigues AM, Sasaki AA, Burger E, de Camargo ZP. Characterization of virulence profile, protein secretion and immunogenicity of different Sporothrix schenckii sensu stricto isolates compared with S. globosa and S. brasiliensis species. Virulence. 2013 Apr;4(3):241–249. pmid:23324498
  34. 34. Freitas DF, Santos SS, Almeida-Paes R, de Oliveira MM, do Valle AC, Gutierrez-Galhardo MC, et al. Increase in virulence of Sporothrix brasiliensis over five years in a patient with chronic disseminated sporotrichosis. Virulence. 2015 Feb-Mar;6(2):112–120. pmid:25668479
  35. 35. Ortega I, Soares Felipe MS, Vasconcelos AT, Lopes Bezerra LM, Da Silva Dantas A. Peroxide sensing and signaling in the Sporothrix schenckii complex: an in silico analysis to uncover putative mechanisms regulating the Hog1 and AP-1 like signaling pathways. Med Mycol. 2015 Jan;53(1):51–59. pmid:25550387
  36. 36. Almeida-Paes R, de Oliveira LC, Oliveira MM, Gutierrez-Galhardo MC, Nosanchuk JD, Zancopé-Oliveira RM. Phenotypic characteristics associated with virulence of clinical isolates from the Sporothrix complex. Biomed Res Int. 2015 Apr:212308.
  37. 37. Carlos IZ, Sassá MF, da Graça Sgarbi DB, Placeres MC, Maia DC. Current research on the immune response to experimental sporotrichosis. Mycopathologia. 2009 Jul;168(1):1–10. pmid:19241140
  38. 38. Fernandes KS, Coelho AL, Lopes Bezerra LM, Barja-Fidalgo C. Virulence of Sporothrix schenckii conidia and yeast cells, and their susceptibility to nitric oxide. Immunology. 2000 Dec;101(4):563–569. pmid:11122461
  39. 39. Ruiz-Baca E, Toriello C, Perez-Torres A, Sabanero-Lopez M, Villagomez-Castro JC, Lopez-Romero E. Isolation and some properties of a glycoprotein of 70 kDa (Gp70) from the cell wall of Sporothrix schenckii involved in fungal adherence to dermal extracellular matrix. Med Mycol. 2009 Mar;47(2):185–196. pmid:18608892
  40. 40. Rodrigues AM, Fernandes GF, Araujo LM, Della Terra PP, dos Santos PO, Pereira SA, et al. Proteomics-Based Characterization of the Humoral Immune Response in Sporotrichosis: Toward Discovery of Potential Diagnostic and Vaccine Antigens. PLoS Negl Trop Dis. 2015 Aug;9(8):e0004016. pmid:26305691
  41. 41. Nascimento RC, Espíndola NM, Castro RA, Teixeira PA, Loureiro y Penha CV, Lopes-Bezerra LM, et al. Passive immunization with monoclonal antibody against a 70-kDa putative adhesin of Sporothrix schenckii induces protection in murine sporotrichosis. Eur J Immunol. 2008 Nov;38(11):3080–9. pmid:18991286
  42. 42. Rodrigues AM, Kubitschek-Barreira PH, Fernandes GF, de Almeida SR, Lopes-Bezerra LM, de Camargo ZP. Immunoproteomic analysis reveals a convergent humoral response signature in the Sporothrix schenckii complex. J Proteomics. 2015 Feb;115:8–22. pmid:25434489
  43. 43. Portuondo DL, Batista-Duharte A, Ferreira LS, Martínez DT, Polesi MC, Duarte RA, et al. A cell wall protein-based vaccine candidate induce protective immune response against Sporothrix schenckii infection. Immunobiology. 2016 Feb;221(2):300–309. pmid:26547105
  44. 44. Hartmann K, Day MJ, Thiry E, Lloret A, Frymus T, Addie D, et al. Feline injection-site sarcoma: ABCD guidelines on prevention and management. J Feline Med Surg. 2015 Jul;17(7):606–613. pmid:26101312